stockrowPrestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
Follow PBH
Alert me
Prestige Consumer Healthcare Inc. (PBH) Operating cash flow
Prestige Consumer Healthcare Inc.'s operating cash flow for fiscal 2026 was $257.6M, unchanged from fiscal 2025. Over the twelve months to 30 September 2026 it was $229.8M. Over the past ten years it has ranged from $148.7M (fiscal 2017) to $259.9M (fiscal 2022); the current reading is higher than 92% of that period. Operating cash flow has risen for 3 consecutive fiscal years. Prestige Consumer Healthcare Inc. ranks 17th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2026 | $257.6M | 2.43% |
| FY2025 | $251.5M | 1.04% |
| FY2024 | $248.9M | 8.36% |
| FY2023 | $229.7M | (11.62%) |
| FY2022 | $259.9M | 10.32% |
| FY2021 | $235.6M | 8.51% |
| FY2020 | $217.1M | 14.71% |
| FY2019 | $189.3M | (9.91%) |
| FY2018 | $210.1M | 41.32% |
| FY2017 | $148.7M | (15.68%) |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $37.9M | (46.51%) |
| Jun 2026 | $70.8M | 65.23% |
| Mar 2026 | $42.8M | (45.28%) |
| Dec 2025 | $78.3M | 36.18% |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | $367.5M |
| TRLV Trulieve Cannabis Corp. compare | $242.5M |
| PRGO Perrigo Company plc compare | $240.6M |
| PBH Prestige Consumer Healthcare Inc. | $229.8M |
| XERS Xeris Biopharma Holdings, Inc. compare | $73.6M |
| ALVO Alvotech compare | −$11.8M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.7M |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −$124.8M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$126.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on PBH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement